stockportfolio.pro
Stocks / ARWR vs MASI
ARWR vs MASI
Arrowhead Pharmaceuticals, Inc. and Masimo Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Arrowhead Pharmaceuticals, Inc. (ARWR) | Masimo Corporation (MASI) | |
|---|---|---|
| Market cap | $10.0B | $9.4B |
| Revenue (latest FY) | $829.45M | $1.53B |
| Net income (latest FY) | $-1.63M | $-151.50M |
| Revenue growth (5y CAGR) | 56.6% | 5.9% |
| Net margin | -0.2% | -9.9% |
| Return on equity | -0.3% | -21.0% |
| P/E ratio | — | 44.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 8 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ARWR — free Open MASI — freeFrequently asked questions
Which is bigger, ARWR or MASI?
Arrowhead Pharmaceuticals, Inc. is larger by market capitalization — $10.0B versus $9.4B.
Which grows faster, ARWR or MASI?
Over the last five fiscal years, Arrowhead Pharmaceuticals, Inc. grew revenue faster — 56.6%/yr versus 5.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.